Comprehensive Support from the Ministry of Health and Welfare and the Ministry of SMEs and Startups: From Clinical Trials to Commercialization
Annual Growth Support System for 50 Promising Companies
Leveraging the Strengths of Each Ministry

The government is establishing a collaborative system to support promising small and venture companies in the pharmaceutical and bio sectors through every stage of their growth, from research and development (R&D), clinical trials, investment and guarantees, commercialization, to global expansion.


Jung Eunkyung, Minister of Health and Welfare (center), is delivering a greeting at the presentation on collaborative measures for the full cycle innovation growth of pharmaceutical bio ventures held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul on March 24. Photo by Yonhap News

Jung Eunkyung, Minister of Health and Welfare (center), is delivering a greeting at the presentation on collaborative measures for the full cycle innovation growth of pharmaceutical bio ventures held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul on March 24. Photo by Yonhap News

View original image

On September 17, at Lunit in Gangnam-gu, Seoul, the Ministry of Health and Welfare and the Ministry of SMEs and Startups held an on-site meeting with CEOs of pharmaceutical and bio SMEs and shared the main details and direction of the “K-Pharmaceutical and Bio Frontier Enterprise Development Plan.”


This plan is designed to select 50 companies each year with growth potential and technological capabilities in new drug development, digital health and medical devices, and bio-materials and production technology, providing tailored, step-by-step support. In particular, for new drug development companies, the support measures are linked across the long-term growth trajectory, from discovering and developing candidate substances, non-clinical testing, preparing and approving investigational new drug (IND) applications, phase 1 to 3 clinical trials, to obtaining product approval and commercialization.


The participating companies at the meeting suggested that support is needed during candidate development and non-clinical stages for technology development as well as testing and validation. As they enter the clinical trial stage, they emphasized the importance of large-scale funding, professional talent, and cooperation with hospitals and clinical institutions. They also pointed out that support should continue even after clinical trials are completed, covering product approval, technology transfer, follow-up investments, and global market entry.


Accordingly, the two ministries plan to build a support system that does not stop at a single R&D project, but instead links and coordinates policy tools along each stage of the corporate growth process, including technology development, clinical trials and demonstration, commercialization, investment and guarantees, and global expansion.


They also agreed on the importance of organically connecting the expertise of each ministry, considering the unique characteristics of the pharmaceutical and bio industry. The Ministry of Health and Welfare will leverage its expertise and infrastructure for clinical trials and commercialization in the pharmaceutical and bio sector, while the Ministry of SMEs and Startups will utilize its capabilities in discovering SMEs, supporting startups, R&D, investment, and commercialization.


Through these efforts, the goal is to build a collaborative support system that enables promising companies to advance beyond technology development to clinical trials, commercialization, and global market entry.


Lee Hyung-hoon, Second Vice Minister of Health and Welfare, said, “In the pharmaceutical and bio industry, systematic support tailored to each stage of corporate growth—from candidate development, non-clinical and clinical trials, to product approval and commercialization—is crucial. Based on feedback from the field, we will work closely with the Ministry of SMEs and Startups to establish a truly effective support system.”


Noh Yong-seok, First Vice Minister of the Ministry of SMEs and Startups, stated, “Even with excellent drug candidates and technologies, pharmaceutical and bio companies require significant time and capital to commercialize and reach the market. By combining the Ministry of SMEs and Startups’ capabilities in R&D, investment, and commercialization with the Ministry of Health and Welfare’s sector expertise, we will actively support the growth of promising enterprises.”





This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing